Kepler Capital Reaffirms Their Buy Rating on Merck KGaA (0O14)
Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...
Deutsche Bank Sticks to Their Buy Rating for Merck KGaA (0O14)
In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Merck KGaA 2024 Sales EUR21.16B
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Merck KGaA Sees Forex-Adjusted Earnings Growth of up to 8% This Year
FRANKFURT (Reuters) - Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by ...
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.